{"id":"d2de09e7-15f9-5c4c-a5bb-85784a481109","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-crat-bypass","predicate":"increases_in_recorded_comparison","statement":"ALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"0e6e4036-c14a-5d10-8bc2-ab2d6f693ac5","mechanism_event_label":"ALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"9b97798e-bd7b-54c6-b5e8-0e8800223543","slug":"human-cancer-histone-acetylation","display_name":"Human cancer-cell histone acetylation","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0e6e4036-c14a-5d10-8bc2-ab2d6f693ac5","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-crat-bypass-event","event_type":"experimental_observation","label":"ALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.","description":"### cancer-crat-bypass\n\nALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.\nSupplying the acetylated product bypassed this perturbation under the tested conditions. The result does not establish a neuron-wide pathway.\nModel and exposure: Human cancer-cell CRAT knockdown; Extended Data Fig. 6c.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"ALCAR added after CRAT knockdown","sequence_order":0,"notes":""},{"entity":{"id":"9b97798e-bd7b-54c6-b5e8-0e8800223543","slug":"human-cancer-histone-acetylation","display_name":"Human cancer-cell histone acetylation","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"6e34c035-9371-578f-b799-fd2a14e9e40f","slug":"l-carnitine","display_name":"L-Carnitine","entity_type_key":"small_molecule"},"role":"nonrescuing comparator","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"supplied","comparator":"CRAT-knockdown cells without ALCAR","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"knocked down","comparator":"CRAT-knockdown cells without ALCAR","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"human-crat","display_name":"Human carnitine acetyltransferase / CRAT","entity_type_key":"protein"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"ALCAR added after CRAT knockdown\", \"comparator\": \"CRAT-knockdown cells without ALCAR\", \"endpoint\": \"ALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"acetylcarnitine\", \"state\": \"supplied\"}, {\"entity_slug\": \"human-crat\", \"state\": \"knocked down\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Human cancer-cell CRAT knockdown; Extended Data Fig. 6c.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"ALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference cancer-crat-bypass; Supplying the acetylated product bypassed this perturbation under the tested conditions. The result does not establish a neuron-wide pathway.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"b48defef-3307-57c7-b262-d266fd8e5342","evidence_kind":"source_excerpt","locator":"Lines 296-302","start_line":296,"end_line":302,"excerpt":"### cancer-crat-bypass\n\nALCAR restored histone acetylation after CRAT knockdown, whereas L-carnitine did not, in the 2026 cancer models.\nSupplying the acetylated product bypassed this perturbation under the tested conditions. The result does not establish a neuron-wide pathway.\nModel and exposure: Human cancer-cell CRAT knockdown; Extended Data Fig. 6c.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Human cancer-cell CRAT knockdown; Extended Data Fig. 6c.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}